Close Menu

NEW YORK (GenomeWeb) - HelixBind, a Marlborough, Massachusetts-based startup, recently became the first entity to receive funding for a molecular diagnostic testing system through CARB-X, an international group intent on combating antibiotic-resistant superbugs.

The HelixBind test system, called RaPID, uses a number of novel approaches, including peptide nucleic acid-, or PNA-based amplification to detect bloodstream infections, said David Steinmiller, the firm's chief business officer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

In Science this week: whole-genome sequencing of single sperm cells, and more.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.